Search

Your search keyword '"Viral Matrix Proteins chemistry"' showing total 1,114 results

Search Constraints

Start Over You searched for: Descriptor "Viral Matrix Proteins chemistry" Remove constraint Descriptor: "Viral Matrix Proteins chemistry"
1,114 results on '"Viral Matrix Proteins chemistry"'

Search Results

1. Assembly and activation of EBV latent membrane protein 1.

2. Insights into the specific feature of the electrostatic recognition binding mechanism between BM2 and BM1: a molecular dynamics simulation study.

3. Conformations of influenza A M2 protein in DOPC/DOPS and E. coli native lipids and proteins.

4. Region-selective and site-specific glycation of influenza proteins surrounding the viral envelope membrane.

5. Membrane curvature sensing and symmetry breaking of the M2 proton channel from Influenza A.

6. Structure-guided mutagenesis targeting interactions between pp150 tegument protein and small capsid protein identify five lethal and two live-attenuated HCMV mutants.

7. Structure and dynamics of the proton-selective histidine and the gating tryptophan in an inward rectifying hybrid influenza B and A virus M2 proton channel.

8. In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40.

9. Assembly of respiratory syncytial virus matrix protein lattice and its coordination with fusion glycoprotein trimers.

10. Virtual screening and molecular growth guide the design of inhibitors for the influenza virus drug-resistant mutant M2-V27A/S31N.

11. High-throughput virtual screening of Streptomyces spp. metabolites as antiviral inhibitors against the Nipah virus matrix protein.

12. A top-down approach for studying the in-silico effect of the novel phytocompound tribulusamide B on the inhibition of Nipah virus transmission through targeting fusion glycoprotein and matrix protein.

13. The impact of transmembrane peptides on lipid bilayer structure and mechanics: A study of the transmembrane domain of the influenza A virus M2 protein.

14. Comparing Multifunctional Viral and Eukaryotic Proteins for Generating Scission Necks in Membranes.

15. Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products.

16. Minor electrostatic changes robustly increase VP40 membrane binding, assembly, and budding of Ebola virus matrix protein derived virus-like particles.

17. Computational and experimental identification of keystone interactions in Ebola virus matrix protein VP40 dimer formation.

18. Cooperative Membrane Binding of HIV-1 Matrix Proteins.

19. The Potential of Cyclodextrins as Inhibitors for the BM2 Protein: An In Silico Investigation.

20. In Situ Spectroscopic Detection of Large-Scale Reorientations of Transmembrane Helices During Influenza A M2 Channel Opening.

21. The C-terminus of Sudan ebolavirus VP40 contains a functionally important CX n C motif, a target for redox modifications.

22. Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation.

23. A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR.

24. Elucidating Residue-Level Determinants Affecting Dimerization of Ebola Virus Matrix Protein Using High-Throughput Site Saturation Mutagenesis and Biophysical Approaches.

25. Inside and outside of virus-like particles HBc and HBc/4M2e: A comprehensive study of the structure.

26. An insight into SARS-CoV-2 membrane protein interaction with spike, envelope, and nucleocapsid proteins.

27. Molecular origins of asymmetric proton conduction in the influenza M2 channel.

28. A Glu-Glu-Tyr Sequence in the Cytoplasmic Tail of the M2 Protein Renders Influenza A Virus Susceptible to Restriction of the Hemagglutinin-M2 Association in Primary Human Macrophages.

29. PSMD12-Mediated M1 Ubiquitination of Influenza A Virus at K102 Regulates Viral Replication.

30. Clustering of tetrameric influenza M2 peptides in lipid bilayers investigated by 19 F solid-state NMR.

31. A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.

32. Identification of novel chemical compounds targeting filovirus VP40-mediated particle production.

33. Emulating Membrane Protein Environments─How Much Lipid Is Required for a Native Structure: Influenza S31N M2.

34. Helical ordering of envelope-associated proteins and glycoproteins in respiratory syncytial virus.

35. Ebola virus protein VP40 binding to Sec24c for transport to the plasma membrane.

36. Ubiquitination on Lysine 247 of Newcastle Disease Virus Matrix Protein Enhances Viral Replication and Virulence by Driving Nuclear-Cytoplasmic Trafficking.

37. Multiscale Simulation of an Influenza A M2 Channel Mutant Reveals Key Features of Its Markedly Different Proton Transport Behavior.

38. Influenza A Virus Infection Activates NLRP3 Inflammasome through Trans-Golgi Network Dispersion.

39. Elucidation of SARS-Cov-2 Budding Mechanisms through Molecular Dynamics Simulations of M and E Protein Complexes.

40. Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease.

41. Respiratory Syncytial Virus Matrix Protein-Chromatin Association Is Key to Transcriptional Inhibition in Infected Cells.

42. Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay.

43. New structural insights into the multifunctional influenza A matrix protein 1.

44. Key Amino Acids of M1-41 and M2-27 Determine Growth and Pathogenicity of Chimeric H17 Bat Influenza Virus in Cells and in Mice.

45. Amino- and carboxyl-terminal ends of the bovine parainfluenza virus type 3 matrix protein are important for virion and virus-like particle release.

46. SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms.

47. Subtype Differences in the Interaction of HIV-1 Matrix with Calmodulin: Implications for Biological Functions.

48. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.

49. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.

50. Water-Triggered, Irreversible Conformational Change of SARS-CoV-2 Main Protease on Passing from the Solid State to Aqueous Solution.

Catalog

Books, media, physical & digital resources